NO941415L - - Google Patents

Info

Publication number
NO941415L
NO941415L NO941415A NO941415A NO941415L NO 941415 L NO941415 L NO 941415L NO 941415 A NO941415 A NO 941415A NO 941415 A NO941415 A NO 941415A NO 941415 L NO941415 L NO 941415L
Authority
NO
Norway
Prior art keywords
mbp
residues
amino acid
synthetic peptides
peptides
Prior art date
Application number
NO941415A
Other languages
English (en)
Other versions
NO310513B1 (no
NO941415D0 (no
Original Assignee
Univ Alberta
Warren Kenneth G
Catz Ingrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta, Warren Kenneth G, Catz Ingrid filed Critical Univ Alberta
Publication of NO941415D0 publication Critical patent/NO941415D0/no
Publication of NO941415L publication Critical patent/NO941415L/no
Publication of NO310513B1 publication Critical patent/NO310513B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19941415A 1991-10-22 1994-04-19 Farmasöytisk preparat inneholdende et peptid som aktiv bestanddel, og anvendelse av et peptid for fremstilling av etmedikament for behandling av multippel sklerose NO310513B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002053799A CA2053799C (en) 1991-10-22 1991-10-22 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
PCT/CA1992/000448 WO1993008212A1 (en) 1991-10-22 1992-10-15 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid

Publications (3)

Publication Number Publication Date
NO941415D0 NO941415D0 (no) 1994-04-19
NO941415L true NO941415L (no) 1994-06-22
NO310513B1 NO310513B1 (no) 2001-07-16

Family

ID=4148603

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19941415A NO310513B1 (no) 1991-10-22 1994-04-19 Farmasöytisk preparat inneholdende et peptid som aktiv bestanddel, og anvendelse av et peptid for fremstilling av etmedikament for behandling av multippel sklerose

Country Status (12)

Country Link
EP (1) EP0610446B1 (no)
AT (1) ATE236193T1 (no)
AU (1) AU2750092A (no)
CA (1) CA2053799C (no)
DE (1) DE69232987T2 (no)
DK (1) DK0610446T3 (no)
ES (1) ES2196007T3 (no)
FI (1) FI111050B (no)
NO (1) NO310513B1 (no)
NZ (1) NZ244807A (no)
RU (1) RU2121850C1 (no)
WO (1) WO1993008212A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
WO2005009455A1 (fr) * 2003-07-29 2005-02-03 Terentiev Alexandr Alexandrovi Composition de peptides presentant une propriete immunoregulatrice
AU2009354040A1 (en) * 2009-10-12 2012-05-31 Lifebio Laboratories Llc Composition for treatment of Multiple Sclerosis
US9326773B2 (en) 2012-01-26 2016-05-03 Covidien Lp Surgical device including buttress material
WO2024094562A1 (en) * 2022-11-01 2024-05-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis

Also Published As

Publication number Publication date
DE69232987T2 (de) 2004-01-29
ES2196007T3 (es) 2003-12-16
DK0610446T3 (da) 2003-07-14
EP0610446B1 (en) 2003-04-02
NZ244807A (en) 1997-08-22
CA2053799C (en) 2002-03-12
NO310513B1 (no) 2001-07-16
ATE236193T1 (de) 2003-04-15
CA2053799A1 (en) 1993-04-23
NO941415D0 (no) 1994-04-19
AU2750092A (en) 1993-05-21
WO1993008212A1 (en) 1993-04-29
DE69232987D1 (de) 2003-05-08
RU2121850C1 (ru) 1998-11-20
FI941860A0 (fi) 1994-04-21
EP0610446A1 (en) 1994-08-17
FI941860A (fi) 1994-04-21
RU94027578A (ru) 1996-10-20
FI111050B (fi) 2003-05-30

Similar Documents

Publication Publication Date Title
DE68916932D1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
NO941415L (no)
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
HUT62916A (en) Process for producing immunogenic peptides and pharmaceutical compositions comprising same
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
NZ293910A (en) Peptides useful in immunoregulation of antibodies to human myelin basic protein, pharmaceutical compositions and method of treatment
IL116559A0 (en) Chimeric proteins
PT970121E (pt) Fragmentos peptídicos de proteína básica de mielina, suas composições farmacêuticas e sua utilização no tratamento de esclerose múltipla
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees